Zacks Investment Research downgraded shares of Odonate Therapeutics (NASDAQ:ODT) from a buy rating to a hold rating in a research note published on Tuesday morning.
According to Zacks, “Odonate Therapeutics, LLC is a pharmaceutical company. It engaged in the development of therapeutics to improve and extend the lives of patients with cancer. The company focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer. Odonate Therapeutics, LLC is based in SAN DIEGO, United States. “
Separately, ValuEngine upgraded shares of Odonate Therapeutics from a sell rating to a hold rating in a report on Wednesday, May 2nd. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Odonate Therapeutics presently has an average rating of Buy and a consensus price target of $31.00.
Shares of Odonate Therapeutics opened at $23.33 on Tuesday, MarketBeat.com reports. Odonate Therapeutics has a 1-year low of $15.15 and a 1-year high of $32.00.
Odonate Therapeutics (NASDAQ:ODT) last announced its quarterly earnings data on Thursday, May 3rd. The company reported ($0.69) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.85) by $0.16. equities analysts forecast that Odonate Therapeutics will post -3.3 earnings per share for the current year.
In other Odonate Therapeutics news, Director Boxer Capital, Llc purchased 100,000 shares of the business’s stock in a transaction that occurred on Monday, March 26th. The shares were purchased at an average price of $22.73 per share, for a total transaction of $2,273,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin C. Tang purchased 14,050 shares of the business’s stock in a transaction that occurred on Thursday, March 1st. The stock was acquired at an average price of $27.42 per share, for a total transaction of $385,251.00. The disclosure for this purchase can be found here. Insiders purchased 142,662 shares of company stock worth $3,442,792 in the last 90 days.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Monashee Investment Management LLC purchased a new position in Odonate Therapeutics in the fourth quarter valued at approximately $3,125,000. Redmile Group LLC purchased a new position in Odonate Therapeutics in the fourth quarter valued at approximately $14,923,000. RTW Investments LP purchased a new position in Odonate Therapeutics in the fourth quarter valued at approximately $725,000. Goldman Sachs Group Inc. purchased a new position in Odonate Therapeutics in the fourth quarter valued at approximately $660,000. Finally, Allianz Asset Management GmbH purchased a new position in Odonate Therapeutics in the fourth quarter valued at approximately $6,088,000. Hedge funds and other institutional investors own 83.18% of the company’s stock.
About Odonate Therapeutics
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc also conducting a Phase III study in MBC, which is known as CONTESSA.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.